Theriva Biologics, Inc.
TOVX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000894158
No open-market purchases or sales by Theriva Biologics, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $495.5K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +4 vs. previous quarter
- 26
- 13F valueReported value at the end of Q2 2026
- $495.5K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding TOVX, Q2 2026
No superinvestor reported holding TOVX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Theriva Biologics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 8, 2023 (view filing) | Jun 7 | 1 day | Shallcross Steven ACEO and CFO | PPurchase | +14.0K | $0.69 | +$9.66K | +5.9%250.0K after | |
| Jun 7, 2023 (view filing) | Jun 6 | 1 day | Shallcross Steven ACEO and CFO | PPurchase | +26.0K | $0.63 | +$16.4K | +12.4%236.0K after | |
| Feb 13, 2023 (view filing) | Feb 10 | 3 days | Shallcross Steven ACEO and CFO | PPurchase | +25.0K | $1.04 | +$26.0K | +13.5%210.0K after | |
| Feb 3, 2023 (view filing) | Feb 2 | 1 day | Shallcross Steven ACEO and CFO | PPurchase | +25.0K | $0.94 | +$23.5K | +15.6%185.0K after | |
| Jan 26, 2023 (view filing) | Jan 25 | 1 day | Shallcross Steven ACEO and CFO | PPurchase | +25.0K | $0.87 | +$21.8K | +18.5%160.0K after | |
| Jan 23, 2023 (view filing) | Jan 20 | 3 days | Shallcross Steven ACEO and CFO | PPurchase | +25.0K | $0.75 | +$18.8K | +22.7%135.0K after | |
| Jan 3, 2023 (view filing)6:04 AM ET | Dec 29, 2022 | 5 days | Shallcross Steven ACEO and CFO | PPurchase | +100.0K | $0.437 | +$43.7K | +1,000.0%110.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Theriva Biologics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 486,179 | $121.5K | 0.00% | +293,775+152.7% | Added |
| Jane Street Group, LLC | 331,922 | $83.0K | 0.00% | +154,888+87.5% | Added |
| Geode Capital Management, LLC | 294,021 | $73.6K | 0.00% | −156,242−34.7% | Reduced |
| Vanguard Fiduciary Trust Co | 241,780 | $60.4K | 0.00% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 112,076 | $28.0K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 87,138 | $22.0K | 0.00% | −166,080−65.6% | Reduced |
| Northern Trust Corp | 82,700 | $20.7K | 0.00% | +82,700 | New |
| Renaissance Technologies LLC | 63,710 | $15.9K | 0.00% | +63,710 | New |
| UBS Group AG | 61,053 | $15.3K | 0.00% | −164,571−72.9% | Reduced |
| XTX Topco Ltd | 53,868 | $13.5K | 0.00% | −40,752−43.1% | Reduced |